A Phase III open-label,multicenter trial of avelumab (MSB0010718C) vs. Platinum-based doublet as a 1st line treatment of recurrent or Stage IV PD-L1 + NSCLC

The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.